Fish, docosahexaenoic acid and Alzheimer’s disease by Cunnane, Stephen C. et al.
DHA-AD PLR 2009-02-08 
Fish, Docosahexaenoic Acid and Alzheimer’s Disease 
Cunnane SC, Plourde M, Pifferi F, Bégin M, Féart C* and Barberger-Gateau P* 
Department of Medicine and Research Center on Aging, 
CSSS-IUGS  
Université de Sherbrooke, Sherbrooke, QC, Canada, and 
* Inserm, U897, Bordeaux, F-33076 France ; Univ Victor Segalen Bordeaux 2, Bordeaux,  
F-33076 France  
 
 
 
Correspondence to: 
Stephen C. Cunnane 
Research Center on Aging 
1036 Belvédère St South 
Sherbrooke, QC, Canada J1H 4C4 
Stephen.cunnane@usherbrooke.ca 
 
 1
DHA-AD PLR 2009-02-08 
Abbreviations: 
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ABSTRACT  
Cognitive decline in the elderly, particularly Alzheimer’s disease (AD), is a major socio-
economic and healthcare concern. We review here the literature on one specific aspect of diet 
affecting AD, that of the ω3 fatty acids, particularly the brain’s principle ω3 fatty acid - 
docosahexaenoic acid (DHA). DHA has deservedly received wide attention as a nutrient 
supporting both optimal brain development and for cardiovascular health. Our aim here is to 
critically assess the quality of the present literature as well as the potential of ω3 fatty acids to 
treat or delay the onset of AD. We start with a brief description of cognitive decline in the 
elderly, followed by a brief overview of well recognized biological functions of DHA. We then 
turn to epidemiological studies, which are largely supportive of protective effects of fish and 
DHA against risk of AD. However, biological studies, including blood and brain DHA analyses 
need careful interpretation and further investigation, without which the success of clinical trials 
with DHA may continue to struggle. We draw attention to some of the methodological issues 
that need resolution as well as an emerging mechanism that may explain how DHA could be 
linked to protecting brain function in the elderly. 
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1.  INTRODUCTION 
Cognitive decline, particularly in the form of Alzheimer’s disease (AD), has emerged in 
the past 20 years as a major challenge to the quality of life for the elderly and their caregivers. 
AD and neurodegenerative diseases in general are putting significant pressure on healthcare 
resources both in developed and developing countries. Once it is clinically diagnosed, there is 
little prospect of improving the prognosis of AD [1]. Hence, to reduce the risk of cognitive 
decline in the elderly, closer attention needs to be paid to the possible impact of lifestyle and 
other non-genetic, hence modifiable, risk factors that are present in younger adults. Diet 
quality is a lifestyle risk factor contributing to AD and chronic degenerative diseases in 
general. One class of dietary nutrients closely associated with optimal function of the brain is 
the ω3 polyunsaturated fatty acids (PUFA), particularly docosahexaenoic acid (DHA; 22:6ω3).  
We review here the possible link between fish intake, DHA and declining cognitive 
function associated with aging, with emphasis on three types of studies in humans – 
epidemiological studies of fish or DHA intake, measurement of blood or brain DHA levels, and 
clinical trials of supplements containing DHA in age-related cognitive decline, AD, or other 
forms of dementia. Animal studies linking DHA to AD will be described briefly but have 
recently been discussed elsewhere [2, 3] and are therefore not the focus of this review. 
 
2.  DECLINING COGNITIVE FUNCTION IN THE ELDERLY 
2.1.  Clinical Aspects 
Dementia is defined as a clinical syndrome which associates a memory disorder and 
impairment in at least one other cognitive domain, both of which significantly interfere with 
social function or activities of daily living [4, 5]. AD is the most frequent cause of dementia, 
accounting for 50-60% of all cases [1]. It is characterized by a progressive decline in memory 
function with objective evidence of impaired episodic memory on neuropsychological testing. 
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Aside from the presence of certain predisposing genetic polymorphisms, several clinical 
features can be used to support the diagnosis of probable AD. These include the presence of 
atrophy in the medial temporal lobe and/or hippocampus on brain imaging, biomarkers in 
cerebrospinal fluid (see Section 2.2 - Neuropathological Features), or specific abnormal 
patterns of brain glucose uptake seen with positron emitting tomography [5]. The diagnosis of 
AD is considered definite only when specific neuropathological criteria are met (see below) or 
when genetic evidence (mutation on chromosome 1, 14 or 21) is present in addition to the 
clinical criteria cited above [5]. 
Before the dementia stage, AD pathology may manifest through subtle cognitive 
decline greater than expected for an individual's age and education but with minimal impact 
on daily living. This transitory and still reversible stage is usually termed mild cognitive 
impairment (MCI), but there is as yet no clear consensus on its definition [6-9]  
 
2.2  Neuropathological Features 
Senile plaques and neurofibrillary tangles in the medial temporal lobe structures and 
cortical areas are the neuropathological hallmark of AD [1]. AD is characterized by the 
accumulation of various β-amyloid (Aβ ) peptides resulting from the cleavage of the amyloid 
precursor protein, in particular peptides composed of 40 (Aβ40) and 42 (Aβ42) amino-acids. 
Aβ is produced constitutively during normal cell metabolism but under normal conditions, 
brain Aβ does not accumulate. According to the amyloid cascade hypothesis [10], the central 
event in AD pathogenesis is an imbalance between Aβ production and clearance, with 
increased Aβ production in familial AD and decreased Aβ clearance in sporadic AD [1]. 
There are several pools of soluble and insoluble Aβ that are normally in equilibrium . 
Soluble forms of Aβ40 and Aβ42 have toxic effects and are thought to be responsible for the 
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severity of the neurodegenerative process in AD [11]. Conversely, the level of insoluble Aβ, 
which is a major part of total amyloid load, distinguishes AD from controls but is not correlated 
with disease severity or number of amyloid plaques [11]. Soluble Aβ species constitute a 
fluctuating intra- and extra-cellular pool whereas insoluble Aβ is usually viewed as relatively 
stable. 
The other characteristic lesion of AD is the presence of intra-cellular neurofibrillary 
tangles composed of abnormally hyperphosphorylated tau protein. Tau pathology is generally 
considered as a downstream event but may contribute to neuronal dysfunction and cognitive 
impairment [1]. AD pathology is also accompanied by synaptic dysfunction and neuronal 
apoptosis. 
 
2.3  Risk Factors 
Old age is the main risk factor for AD since the prevalence of AD increases almost 
exponentially from 1% at 60-64 years old to 25 % or more at 85 years old and older [1]. The 
presence of certain predisposing genetic polymorphisms can also greatly increase the risk of 
AD. Mutations in the amyloid precursor protein, presenilin 1 and presenilin 2 genes have been 
identified in the familial form of AD, a rare autosomal dominant disorder with onset before 65 
years old. In sporadic late-onset AD, presence of the ε4 allele of the apolipoprotein E gene 
(ApoE4) is a significant predisposing factor which lowers the age at onset [12] (see also 
Section 6.2.2 - Apolipoprotein E).  
Risk of AD is also associated with reduced brain ‘reserve capacity’, a parameter linked 
to lower education and insufficient activities that are cognitively and/socially stimulating, i.e. 
puzzles, crosswords or card games [1]. Risk factors for vascular disease also increase the 
risk for AD, including hypertension, dyslipidemia, atherosclerosis, smoking, diabetes, obesity 
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[1]. Conversely, nutritional factors such as anti-oxidants, B vitamins, and ω3 PUFA such as 
DHA may have a potentially protective effect [13-15]. 
 
3.  BIOLOGICAL FUNCTIONS OF DHA 
As the biological functions of DHA have been the matter of a recent extensive review 
[3], here we will only briefly summarize putative mechanisms of action by which it might 
reduce the risk of cognitive decline or AD. In addition to specific functions in the brain, DHA 
has several non-specific properties which could also potentially contribute to its protective 
effect against the neurodegenerative process in AD. 
 
3.1  Neuronal Membranes 
DHA is a major component of the lipids in neuronal membranes where it clearly exerts 
a structural and functional role. The physical state of the neuronal membrane is critical in the 
control of transfer of the neuronal information, i.e. neither too rigid nor too fluid for the ionic 
exchange between the inner and outer walls of the membrane [16]. DHA also modulates 
properties of the hydrophobic core of the membrane bilayer, including conferring a high 
degree of flexibility and directly interacting with membrane proteins, thereby impacting on 
speed of signal transduction, neurotransmission, and formation of lipid rafts [17].  
 
3.2  Amyloid β 
Many in vitro and animal studies suggest a direct role of DHA on Aβ  [2] (see also 
Section 7 - Animal Models) In various animal models and using a variety of experimental 
protocols, DHA exerts a protective effect against neuropathological signs of AD, including Aβ 
accumulation, synaptic marker loss, and hyperphosphorylation of tau [18]. The DHA-derived 
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mediator, neuroprotectin D1 (NPD1), is formed in the brains of AD patients as well as in 
human brain cells in culture. In cytokine-stressed human neural cells, DHA attenuates Aβ 
secretion, an effect accompanied by the formation of NPD1. NPD1 promotes brain cell 
survival via the induction of anti-apoptotic and neuroprotective gene-expression programs that 
suppress Aβ42-induced neurotoxicity [19]. Enrichment of membranes with DHA protects 
neurons in culture against apoptosis when exposed to soluble Aβ [20]. This protective effect 
depends on the way the experiment is conducted; pre-treatment with eicosapentaenoic acid 
(EPA, 20:5ω3) and DHA can actually reduce the survival of neurons incubated with Aβ42, but 
this deleterious effect was not observed when EPA and DHA were added at the same time as 
the Aβ42 peptide [21].  
In living human beings, Aβ measurements can be performed in CSF or in plasma, the 
most convenient fluid to sample for clinical studies. Despite controversy regarding their ability 
to predict AD, plasma Aβ40 and Aβ42 concentrations and their ratio have been proposed as a 
measure of the impact of treatments in clinical AD trials [22, 23]. The possible efficacy of DHA 
in the treatment of AD could therefore potentially be evaluated by its ability to reduce the 
plasma level of soluble Aβ [11]. However, to our knowledge, Aβ concentration has not yet 
been measured in any of the few clinical trials assessing the impact of ω3 PUFA 
supplementation against cognitive decline or dementia in humans (see Section 5.3 - Clinical 
Trials).  
 
3.3  Cardiovascular Properties 
The protective effect of EPA and DHA in cardiovascular disease is well documented in 
humans [24], in particular through randomized controlled trials (RCT) [25-28].Elevated plasma 
triacylglycerols (TG) are a component of the metabolic syndrome which is linked to higher risk 
 9
DHA-AD PLR 2009-02-08 
of cognitive decline, in particular in the presence of elevated inflammation [29]. More 
specifically, elevated plasma TG are a risk factor for dementia, in particular of the vascular 
type [30, 31]. In obese mice, lowering TG with gemfibrozil reversed cognitive impairment [32].  
One of the main effects of dietary ω3 PUFA is to reduce elevated plasma TG [28, 32-
41]. The hypotryglyceridemic effect of ω3 PUFA is believed to be due mostly to their potent 
enhancement of lipolysis through activation of peroxisome proliferator-activated receptors 
(PPAR; see Section 3.6 - Nuclear Receptors) [38]. Therefore, if supplemental DHA or EPA 
were to be shown to have a protective effect against cognitive decline or AD, the mechanism 
might well involve TG lowering.  
 
3.4  Anti-inflammatory Properties 
Inflammation plays a major role in the development and progression of AD. The 
accumulation of Aβ in AD is accompanied by an inflammatory response resulting from 
microglia activation and recruitment of astrocytes, inducing the expression of pro-
inflammatory cytokines [23, 42]. In turn, cytokines stimulate Aβ synthesis and amyloid 
formation, setting off a vicious circle of exacerbation of inflammation [23]. Overproduction of 
reactive oxygen species by brain cytokines increases oxidative stress and hence the risk of 
neurodegeneration [43]. Transient acute systemic inflammation also increases the 
vulnerability of the brain to neurodegenerative disease [44]. 
Long-chain PUFA are viewed as potent modulators of inflammation. Most of the 
mediators formed from EPA and DHA (leukotrienes, resolvins, NPD1) are anti-inflammatory, 
whereas those formed from the ω6 PUFA, arachidonic acid (ARA, 20:4ω6) are mostly pro-
inflammatory [3, 45]. The anti-inflammatory effects of ω3 PUFA could therefore contribute to 
their protective effect against neurodegeneration. 
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Very few RCT have assessed the impact of DHA or EPA supplementation on 
peripheral inflammatory markers in various diseases and the few that have been reported are 
of small sample size and have shown inconsistent results [36, 46-50]. In the OmegAD trial 
conducted in patients with mild to moderate AD receiving 1.7 g DHA and 0.6 g EPA daily, 
increased plasma concentrations of EPA and DHA were associated with reduced release of 
interleukin-1β, interleukin-6 and granulocyte colony-stimulating factor from peripheral blood 
mononuclear cells [51], results supporting a dampening effect of EPA and DHA on peripheral 
inflammatory markers.  
 
3.5  Oxidative Stress 
Oxidative stress results from an imbalance between formation and degradation of pro-
oxidants or decreased cellular antioxidant protection mechanisms, and may result in 
increased cell damage and apoptosis. Excessive oxidative stress stimulates multiple 
signalling pathways in the central nervous system that then participate in pathophysiological 
processes leading to cell damage and, eventually, cell death [52]. The brain is particularly 
susceptible to oxidative stress because, on the one hand, it has a high content in easily 
peroxidizable long-chain PUFA, in particular DHA and ARA, and on the other hand, because 
mitochondrial function to fuel the brain’s normal energy requirements consumes a lot of 
glucose, a process associated with relatively high production of free radicals [53].  
In AD, the accumulation of Aβ is associated with increased free radical production and 
increased lipid peroxidation in the brain [53]. In post-mortem brain samples from AD patients, 
oxidative damage can be observed in the form of oxidized lipids, proteins and DNA (Choi et 
al. 2004 J Biol Chem). Important oxidative damage has also been observed in subjects with 
MCI, suggesting an early role of oxidative stress [54]. 
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DHA administration exerts antioxidant activity as shown by increasing glutathione 
reductase activity and decreasing accumulation of lipid peroxide and reactive oxygen species 
in the cortex and hippocampus of AD model rats [55, 56]. Moreover, a transgenic mouse 
model of AD given an ω3 PUFA deficient diet exhibited increased oxidative damage [57]. 
Some animal models of ischemia-reperfusion brain injury show significant free radical 
scavenging capacity of DHA and protection against peroxidative damage of lipids and proteins 
in developing and adult brains,  with attenuation of neuron loss and cognitive and locomotor 
deficits [17]. However, in a cellular model, DHA did not prevent the oxidative stress induced in 
vitro in neurons exposed to soluble Aβ peptides [20, 42]. 
The few human studies examining the impact of DHA supplementation on oxidative 
stress have yielded inconsistent results. In a double-blind controlled trial, 59 subjects were 
randomized to 4 g/d of purified EPA, DHA, or olive oil for 6 weeks while maintaining their 
usual diet. In one study, urinary F2-isoprostanes, a measure of lipid peroxidation, were 
significantly decreased by dietary EPA or DHA in type 2 diabetic subjects [47]. Plasma 8-iso-
PGF2α was significantly decreased after 3 months of supplementation with ω3 PUFA [58], also 
suggesting inhibition of ARA metabolism to eicosanoids and/or a possible antioxidant effect of 
EPA and DHA. However, supplementation of healthy adult men with high dose of EPA and 
DHA (total 5.3 g/d) may also increase lipid peroxidation, an effect not suppressed by high 
dose vitamin E (900 IU/d) [59]. Therefore, DHA supplementation at low doses may be 
protective against oxidative stress, whereas higher DHA doses promote lipid peroxidation 
[60]. The DHA response to oxidative stress may also be linked to the production of NPD1 
generated enzymatically from unesterified DHA. NPD1 may in turn inhibit oxidative stress or 
have other neuroprotective functions at the site where the free DHA is produced [61, 62]. 
NPD1 production may be influenced by redox balance and availability of other antioxidants.  
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3.6  Nuclear Receptors 
Changing fatty acid intake, particularly PUFA, is an important means of modulating 
gene expression in various tissues [63, 64]. EPA and DHA interact with at least four families 
of transcription factors – peroxisome proliferator-activated receptors (PPAR), liver retinoid X 
receptors, hepatic nuclear factor-4α and sterol regulatory-element-binding protein. EPA and 
DHA also generate a large range of eicosanoids modulating transcription factor activity [65]. 
PPARs are ligand-inducible transcriptional factors with a central role in regulating gene 
expression. PPARs belong to the class II superfamily of nuclear receptors which also includes 
retinoic acid receptors (RAR). RXR, the receptor of 9-cis retinoic acid, is considered as the 
common dimerisation partner of several other nuclear receptors in particular PPARs [66].  
Among the three known isoforms of PPAR (α, β/δ and γ), PPARγ is the most studied, 
partly because of its ability to inhibit inflammatory gene expression in brain cells [67, 68]. 
PUFA bind PPARs with a higher affinity than saturated or monounsaturated fatty acids and 
induce gene transcription by interacting with distinct DNA promoter sequences in the target 
genes predominantly in the form of PPAR/RXR heterodimers [69, 70]. Modulation of the 
expression of genes targeted by PPAR may well also be affected by dietary intake of ω3 
PUFA because of the high efficacy of ω3 PUFA as PPAR ligands [3, 71].  
RAR and RXR play key roles in many aspects of brain development, including 
neurogenesis during embryogenesis, morphological differentiation of catecholaminergic 
neurons, and activity-dependent plasticity [17]. RAR and RXR are also highly expressed in the 
hippocampus, which may be relevant to understanding the role of DHA in AD. Several studies 
show that DHA can specifically bind to and directly activate RXR, leading to the regulation of 
the expression of genes usually under the control of retinoic acid [72-74]. These results may 
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have potential cerebral consequences since the retinoic acid signalling pathway is involved in 
the maintenance of synaptic plasticity and mnesic performances in aged animals [75-78]. In 
humans, a link between the metabolism of retinoids and late onset AD was recently proposed 
[79, 80].  
 
4.  EPIDEMIOLOGICAL STUDIES 
4.1 Prospective Studies 
We turn back now from the biological functions of DHA to its possible role in the link 
between fish, ω3 PUFA intake and AD. The strongest support for a causal association 
between low fish and/or low DHA intake in AD comes from prospective epidemiological 
studies conducted in France, the Netherlands, Scandinavia, Italy and the USA. Of the nine 
such prospective studies that have been published, most show that higher intake of fish or 
long-chain ω3 PUFA decreases the risk of cognitive decline, dementia or AD in the elderly 
(Table 1).  
The Rotterdam Study was the first to report that fish intake protected against the risk of 
AD [81]. However, at just 2 years, the initial follow-up period of this study was relatively short. 
In fact, in the subsequent 6 year follow-up of this cohort, no significant relationship was 
observed between fish intake and risk of AD or all cause dementia [82]. A lower risk of 
incident dementia or cognitive decline in those consuming more fish has nevertheless been 
reported in several other independent prospective cohort studies [83-88].  
Only one prospective study has not shown a significant benefit of higher fish intake and 
risk of AD [89]. This study was based on a subsample of 488 participants representing about 
25% of the main cohort in which both dietary DHA intakes were calculated and plasma DHA 
measurements made. A protective effect of higher plasma DHA was observed against the risk 
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of all cause dementia but not for AD. This negative finding for AD per se may have been due 
to a lack of statistical power because the 50% risk reduction for AD in subjects consuming fish 
more than twice a week was almost statistically significant (95% CI 0.20-1.27; P=0.14). 
Furthermore, several studies suggest that polymorphisms in Apolipoprotein E (ApoE) may 
inhibit or prevent the beneficial effect of fish in reducing the risk of cognitive decline in the 
elderly (see Section 6.2.2 - Apolipoprotein E). 
 
4.2  Cross-Sectional Studies 
Three cross-sectional studies describe better cognitive performance on various 
neuropsychological tests in middle-aged [90] and older persons [91, 92] who regularly 
consumed fish. In these studies, consumption of fish other than fried fish was also associated 
with lower prevalence of subclinical infarcts and white matter abnormalities on brain images in 
older persons, thereby indicating a lower risk of vascular dementia [93]. Despite the 
association between higher fish consumption and better cognitive performance reported in 
these cross-sectional studies, this type of study cannot ascertain causality, i.e. whether the 
observed dietary behaviour is the cause or the consequence of cognitive impairment. Indeed, 
dementia is accompanied by a progressive loss of autonomy in activities of daily living which 
impairs the ability for shopping, preparing adequate meals, and eventually eating well. Hence, 
the value of observational epidemiological studies in understanding the link between dietary 
intake of fish or DHA and risk of dementia or cognitive decline depends crucially on their 
design. 
 
4.3 Fish Intake Compared to DHA Intake 
DHA intake is normally a direct function of fish and seafood intake [89, 94, 95]. The two 
principal reasons for this direct association are that – (i) on a population basis, there is almost 
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no other dietary source of DHA other than fish or seafood and, (ii) the conversion rate from α-
linolenic acid and EPA to DHA through the desaturation-chain elongation system is very 
limited in humans and has essentially no impact on plasma DHA [96, 97].  
Despite the clear association between fish and seafood intake and DHA intake, DHA 
intake is not as clearly linked to lower risk of AD as is fish intake [98]. A precise quantitative 
estimate of DHA intake is generally impossible from food frequency questionnaires because 
the number of fish items they provide is too limited and commonly not adequately validated 
for this purpose. Moreover, EPA and DHA intake has high day-to-day variability because fish 
and seafood intake is typically sporadic. Random within−person error due to day-to-day 
fluctuation in dietary intake and measurement error tends to bias relative risks toward 1, i.e. to 
underestimate the strength of the possible association between the exposure (DHA intake) 
and the outcome (cognitive status) [99]. 
Moreover, consistency between fish and DHA intake in disease associations as such 
AD depends on the power of the study to detect an association, which itself is strongly linked 
to the total number of subjects involved (not only AD cases). In spite of appropriate 
adjustments, other residual confounders in observational studies usually remain: (i) Fish 
consumers differ from non-consumers in many ways which may themselves be associated 
with higher or lower risk of dementia e.g. education, income, lifestyle [91]. (ii) Fish is not eaten 
alone but is a component of “healthy” dietary pattern e.g. the Mediterranean diet itself 
associated with lower dementia risk [100]. Moreover, the recently identified interaction of AD 
risk with ApoE genotype requires stratification on ApoE4 status for a proper interpretation of 
the association between fish or DHA intake and dementia (see Section 6.2.2 - Apolipoprotein 
E).  
 
 16
DHA-AD PLR 2009-02-08 
5. BIOLOGICAL STUDIES OF DHA IN AD AND OTHER FORMS OF COGNITIVE 
DECLINE 
5.1 Blood DHA 
Lower blood DHA occurs in those consuming low amounts of fish while higher plasma 
DHA is observed in those consuming more fish [89, 101]. Indeed, lower blood DHA is 
observed in those adhering to a diet strictly avoiding fish or seafood, i.e. in vegans [102]. The 
amount of DHA in human blood is normally significantly positively correlated to DHA intake, 
but at DHA intakes >2 g/d, DHA in plasma phospholipids approaches saturation and 
increases only marginally thereafter [97]. Since AD and other forms of cognitive decline are 
significantly associated with low fish intake and lower DHA intake (Table 1), one would 
normally expect to see that AD was associated with lower plasma and erythrocyte DHA. We 
review here the evidence for this prediction from both prospective and cross-sectional studies. 
 
5.1.1 Blood DHA - Prospective Studies 
Five published prospective studies have reported plasma DHA in the elderly with 
cognitive decline after follow-up [103-105] or who converted to AD or other dementia [105, 
106] (Table 2; Figure 1). Of these five prospective studies, only the one by Heude et al., [104] 
reported significantly lower plasma DHA. Therefore, a crucial point is that although mean 
plasma or erythrocyte DHA is not different from control values in most prospective studies, 
these studies nevertheless demonstrate a significant inverse association between baseline 
plasma or erythrocyte DHA and risk of cognitive decline or incident dementia [89, 103, 106, 
107]. For instance, the largest prospective study to date was conducted in a subsample of the 
Three City study [106]. It showed that for each increase of one standard deviation in plasma 
DHA, risk of all-cause dementia was reduced by 24%. Nevertheless, mean blood DHA in 
those converting to AD compared to those that did not convert was similar in both groups. In 
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the Three City study [106], the association of higher blood DHA to lower risk of cognitive 
decline became non-significant in multivariate analyses, but the inverse association with 
plasma EPA remained.  
The longest prospective study of the association between DHA intake, plasma DHA 
and cognitive decline in the elderly had a mean follow-up of 9.1 years. It reported that risk of 
all causes of dementia was significantly associated with both lower DHA intake and lower 
DHA in plasma phosphatidylcholine [89]. This study also showed a significantly reduced risk 
(~50%, p=0.05) for all-cause dementia in the highest quartile of plasma DHA [89]. However, 
the direct association between lower DHA intake and higher risk of all causes of dementia 
was present only when the lower three quartiles of DHA intake were combined and compared 
to the highest DHA intake. It was also only significant for all causes of dementia but not for 
AD alone. Apart from the large number of subjects studied, one of the strengths of this study 
was the assessment of DHA intake and plasma DHA in a specific class of blood 
phospholipids (phosphatidylcholine).  
In the study by Beydoun et al. [103] which was base don the Atheroscleosis Risk in 
Communities study, higher plasma phospholipid or cholesteryl ester content of EPA and DHA 
was protective against decline in verbal fluency. However, no association was found with 
global cognitive decline or other neuropsychological tests in that study. In the placebo arm of 
the FACIT trial, higher long chain ω3 PUFA in plasma cholesteryl esters was associated with 
less cognitive decline over 3 years on tests of sensorimotor speed and complex speed but in 
contrast to Beydoun et al [103], was unrelated to changes in word fluency [107]. The largest 
prospective study reporting fatty acid analyses showed a significantly decreased risk of global 
cognitive decline with higher erythrocyte EPA, DHA and total ω3 fatty acids [104]. Hence, it is 
very important to make a distinction between static blood DHA measurements in those with or 
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without cognitive decline, versus the more dynamic measure of blood DHA in relation to risk 
of cognitive decline.  
 
5.1.2  Blood DHA - Cross-sectional Studies  
There are more published reports of blood DHA in dementia, AD or other forms of 
cognitive decline that are based on cross-sectional studies than there are based on 
prospective studies. Nevertheless, relative to each study’s own controls, our post hoc analysis 
is that overall mean blood DHA values for AD or other forms of cognitive decline is still not 
different from 100%, i.e. not different from blood DHA in healthy age-matched controls (Figure 
2). If one outlying cross-sectional study [108] is deleted from this analysis, overall blood DHA 
values in AD and other forms of dementia relative to controls is actually numerically (but not 
statistically) lower in these pooled cross-sectional studies than in the prospective studies 
(compare Figures 1, 2). The lack of association of low blood DHA with AD in cross-sectional 
studies may also be due in part to modification of dietary intake during progression towards 
dementia and the related difficulties that subsequently arise in activities of daily living such as 
shopping or preparing meals. 
Three key points emerge from this post hoc analysis of the published literature: First, 
compared to control values, blood levels of DHA (plasma or erythrocytes) are not different in 
AD or other forms of dementia, regardless of whether the studies are prospective or cross-
sectional in design (Table 2, Figures 1,2). Second, without reference to changing cognitive 
function (preferably in a prospective study design), blood DHA values alone are not a very 
useful measure of cognitive status. Third, it remains to be established whether the overall 
similarity in plasma and erythrocyte DHA levels seen in AD as in healthy age-matched 
controls is a function of masking due to genotype effects, other aspects of study design 
including the generally small numbers of subjects in most cross-sectional studies, or mixing of 
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data for cognitive decline of different etiology. Alternatively, they may also be a function of 
changes in DHA metabolism brought on by cognitive decline itself (see Section 6 - Linking 
Epidemiological and Biological Studies) [109].  
 
5.2 Brain DHA  
 If low DHA intake increases the risk of deteriorating cognition in the elderly, to 
understand the link between dietary DHA and risk of declining cognition in the elderly, it is 
important to know whether low brain DHA occurs in those with clinical evidence of cognitive 
decline, particularly AD. Our analysis here is based on about 100 brain DHA analyses from 
AD patients and age-matched controls reported in seven independent publications (Table 3). 
For the hippocampus, the three published studies all showed AD brain had 30-50% lower free 
DHA and also lower DHA in brain PE. However, in the parahippocampus, brain DHA was not 
different in AD compared to healthy, age-matched controls. Barring the results of one study 
[110], overall values for DHA in frontal cortex phospholipids were variable but, on average, 
also very similar in AD compared to healthy controls (Table 3; Figure 3). Phospholipids are 
the brain’s main repository of DHA but this pool may not be as important as free DHA could 
be in helping the brain resist the oxidative damage occurring in AD. Free DHA is more labile 
and although only one reports gives values for free DHA (in the hippocampus), they were 
50% lower in AD than in controls [19] (Table 3; Figure 3).  
However, when low brain DHA was observed, it was rarely specific for DHA: either 
ARA and/or adrenic acid (22:4ω6) were also decreased [110-112]. In some reports, lower 
DHA concentration was specifically due to a decrease in one of the brain phospholipid 
classes, most commonly plasmalogens but not in the % composition of DHA itself in the 
individual phospholipid classes [113]. In AD, increases of up to 30% in the DHA content of 
frontal cortex, superior and middle temporal and in the white matter of parietal and frontal 
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cortex have also been reported [113-115]. Four fold higher adrenic acid has been observed 
for the gray matter of parietal and frontal cortex and in the parahippocampal region [113-115]. 
Thus, there is considerable disparity and non-specificity for DHA data in AD brain. Indeed, 
there is actually more agreement about the importance of a significant decrease in the 
concentration of brain phospholipids in AD, particularly in plasmalogen PE, than there is 
about changes in brain DHA per se [109]. The changes in brain phospholipid (or free fatty 
acid) pool size during AD may be equally or more important than the possible changes in fatty 
acid composition of these lipid classes [116].  
One difference between these studies that might help account for this disparity of brain 
DHA data is that different researchers have used different criteria to define their AD groups. 
PL and DHA content of brain tissue also varies markedly from region to region [117], 
especially from white to gray matter. Hence, imprecise dissection of brain tissue used in these 
analyses could also markedly skew the results. Nevertheless, one report shows lower DHA in 
both white and gray matter [110]. Possible differences in analytical methodology are not 
always easy to identify but could also contribute to variation in reported DHA values. 
Aside from methodological issues, homeostatic mechanisms slow down brain DHA 
loss during dietary ω3 PUFA deprivation [118], so this might affect the rate of decline of brain 
DHA in the elderly or in response to processes precipitating AD. Animal studies suggest that 
plasma DHA varies much more than brain DHA and is much more influenced by dietary ω3 
PUFA intake. Hence, even if mild, chronic dietary ω3 PUFA (Table 1) might help the AD brain 
resist losing DHA, at least until the stage at which neurodegeneration and lipid peroxidation 
were extensive.  
The natural atrophy of the human brain as it ages [119] adds a complication to 
expression of brain fatty acid data because it affects the point of reference, whether it be 
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tissue weight (dry or wet), phospholipid content or protein or DNA content (See Section 6.2.1 
– DHA Metabolism During Healthy Aging). Nevertheless, in AD, DHA seems to be markedly 
lower in the hippocampus, a brain region intimately involved in memory formation and 
retrieval (Figure 3). It remains to be determined whether this relatively specific change in brain 
DHA is in part a function of inadequate DHA intake or specific pathological mechanisms more 
rapidly destroying DHA in the hippocampus than elsewhere in the brain. 
 
5.3  Clinical Trials 
Converging results from animal and observational studies show a protective effect of 
dietary consumption of fish or ω3 PUFA for risk of AD but, to date, just a single randomized 
controlled trial (RCT) has been reported for the primary prevention of cognitive decline by 
EPA and DHA [120]. In that study, 302 cognitively healthy older participants were randomly 
assigned to receive either 1,800 mg/d EPA+DHA, 400 mg/d EPA+DHA, or placebo capsules 
for 26 weeks. There were no significant differential changes in any cognitive domain among 
the three groups at either 13 or 26 weeks intervention except slightly more decline in memory 
at 13 weeks in the 400 mg group than the placebo, a difference that might well be attributable 
to chance. An interaction with ApoE genotype was observed, i.e. ApoE4 carriers in both fish 
oil groups showed an improvement on the cognitive domain of attention after 26 weeks of 
intervention compared with placebo. However, such post-hoc analyses in small subgroups 
must be interpreted with caution, all the more since the interaction was no consistent with that 
found in observational studies [84, 86, 103].  
Several RCTs have focused on patients who already suffered from various stages or 
types of dementia or cognitive impairment. To date, the largest, published double-blind RCT 
in mild to moderate AD recently showed very modest cognitive benefits of a mixed dietary 
PUFA supplement containing both DHA (1.7 g/g) and EPA (0.6 g/d) compared to a corn oil 
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placebo [121]. No overall difference in cognitive function assessed by the Mini-Mental Status 
Examination (MMSE) or the modified cognitive portion of the Alzheimer Disease Assessment 
Scale (ADAS-cog) was observed between the controls and the intervention group after the 
first 6 months of active or placebo treatment. However, in a sub-group of 32 AD patients who 
had a relatively high level of cognitive function at the start of the study, (MMSE >27), MMSE 
scores declined significantly more slowly during the first 6 months of active treatment [121]. 
Interestingly, cognitive decline seemed to halt when the placebo group also received the ω3 
supplementation during the 6 following months. Again, such post-hoc analyses must be 
interpreted with caution since the randomization was not stratified by cognitive level and could 
not therefore ensure that the placebo and intervention groups were still comparable.  
Similar results were reported in a recent small RCT [122]. The placebo and the 
treatment groups were patients at varying stages of AD or cognitive impairment. They 
consumed a mono-therapy of 1080 mg of EPA and 720 mg of DHA or olive oil esters as the 
placebo for 6 months. ADAS-Cog test scores improved significantly in the EPA+DHA group 
compared to the placebo but only in those with mild cognitive impairment. This study also 
showed that higher % EPA in erythrocytes was significantly associated with better cognitive 
outcome, suggesting that DHA may not be the only ω3 PUFA linked to better cognition [122].  
In an exploratory preventive RCT [123], 49 healthy elderly women received a DHA 
supplement or placebo for 4 months with or without lutein. Multiple cognitive tests measuring 
verbal fluency, memory processing speed and accuracy were performed at randomization 
and 4 months later. DHA alone or in combination with lutein significantly improved verbal 
fluency, whereas rate of learning and delayed recall were improved only in the group 
receiving the DHA plus lutein supplement [123]. DHA supplementation caused no change on 
any other test. Higher DHA serum level was significantly associated with better verbal fluency. 
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However, this small trial had several limitations, including a high rate of dropouts not taken 
into account by an intention-to-treat analysis (14%), and an important ceiling effect on most 
cognitive tests which prevented any improvement. 
Three other small preliminary trials of supplements combining DHA and EPA or DHA 
and ARA in patients with various forms of dementia have also been reported, and all three 
showed that the supplement had no clear benefit for cognitive function [121]. In Japan, a very 
small RCT on 20 patients suffering from dementia from thrombotic cerebrovascular disease 
showed an improvement in MMSE score with 720 mg DHA/d for 6 months [124]. Conversely, 
a small open-label pilot study on the efficacy of ethyl-EPA (500 mg twice daily over 12 wk) for 
the treatment of patients with mild to moderate AD did not demonstrate any effect on 
cognition [125]. Finally, a double-blind RCT that evaluated the impact of 1.5 g/d of EPA+DHA 
for 12 weeks in 190 mildly depressed individuals did not observe any benefit on mood or 
cognitive function [126].  
Hence, at best, a very modest clinical benefit of mixtures of PUFA including DHA has 
been reported but it is not yet clear whether DHA itself has any effect on aging-associated 
cognitive decline or AD. Several aspects of the clinical trials with DHA or other PUFA will 
need further study before conclusions can be drawn about the efficacy of such dietary 
interventions to improve various features of cognition. First, the breadth of doses of DHA used 
in these studies covered a 36 fold range - 120 mg/d to 4.3 g/d (see Table 4), a huge range 
that, importantly, produced no apparent dose-related effects on cognition. Second, two of 
these clinical trials raised the possibility that a beneficial effect of supplemental DHA may 
exist when cognitive decline is mild but that supplemental DHA may not necessarily be 
recommended when the decline is more severe, possibly because additional DHA might 
contribute to degenerative processes in the brain related to lipid peroxidation [121, 122]. 
Third, only one of these studies [120] separated the groups according to ApoE4 genotype, a 
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factor which may well compromise the protective effect of dietary ω3 PUFA in lowering the 
risk of progression towards serious forms of cognitive decline (see Section 6.2.2 - 
Apolipoprotein E).  
 
6.  LINKING EPIDEMIOLOGICAL AND BIOLOGICAL STUDIES 
A link is starting to emerge between lower fish intake, lower DHA and heightened risk 
of AD (Table 1). However, our interpretation is that this link is still tentative. For instance, 
within the prospective studies, three studies tentatively linking estimated DHA intake from fish 
and seafood to lower risk for dementia and AD were not consistent (Table 1): The Zutphen 
study reported a protective effect of total DHA+EPA intake against cognitive decline [127] 
which was not found in the CHAP study (which only reported total ω3 fatty acid intake) [88]. 
Conversely, the latter showed a protective effect of DHA intake specifically against AD without 
reporting about other causes of dementia [87]. In a subsample of the Framingham study, the 
opposite was observed, i.e. protection by DHA against all cause dementia but not AD [89]. 
Also, at least statistically, low fish intake seems to have a stronger association with risk of AD 
than does low DHA intake. Hence, it seems premature to conclude that the protective effect of 
fish against risk of AD can be equated to a protective role specifically of DHA.  
The presumed link between lower fish (or DHA) intake and lower blood DHA in AD is 
also very tentative (Figures 1,2), in part because blood DHA data in AD have fairly wide 
dispersion. Brain DHA data for AD also vary considerably. Three studies do suggest that DHA 
may be lower in the hippocampus in AD (Figure 3), it is not clear that this effect is specific for 
DHA, either in the hippocampus or in other brain regions that have been studied. Currently, 
no studies link blood or brain DHA to the neuropathology specific to AD but such a 
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relationship would greatly strengthen a mechanistic link between low DHA and specific 
processes contributing to AD. 
Hence, broadly, there are two possibilities: either there really is no biological link 
between risk of AD and low DHA intake, low blood or low brain DHA or, owing methodological 
or other experimental differences between studies, the moderately good link present in the 
epidemiological literature is simply not clearly revealed in the biological literature as it 
presently stands, perhaps because features of most of the studies mask or confound the 
variables under study. Some of the methodological challenges affecting the possible 
relationship between fish intake, DHA intake and risk of AD will be discussed first; biological 
reasons for the masking of such a possible relationship will be discussed subsequently (see 
Section 6.2 - Biological Issues). 
 
6.1 Methodological Issues 
The possible relationship between DHA intake and AD is vulnerable to the classical 
pitfalls of nutritional epidemiology affecting observational studies. One major limitation is that 
despite appropriate adjustments, residual confounders still contribute importantly to the 
variability observed. Higher DHA intake may also merely be a marker of a generally protective 
lifestyle including a healthy diet, cognitive and physical activities, and better management of 
vascular risk factors, all of which could contribute to maintain optimal brain functioning during 
aging but for which complete adjustment cannot be achieved.  
Observational studies also face the difficulty of estimating true quantities of dietary 
intake of specific nutrients due to cumulative sources of variability and error, i.e. day-to-day 
intra-individual variability, reliability of food frequency questionnaires, dietary recall, and food 
composition tables. Most published reports have not considered cooking methods but 
concentrations of EPA and DHA in plasma phospholipids may correlate more with 
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consumption of non-fried but not with fried fish [95]. Moreover, it is impossible to differentiate 
the specific effects of a nutrient such as DHA from those of another one to which it is closely 
linked in the usual diet (see Section 6.2.3 - Other Nutrients in Fish). Some of the lack of 
agreement between observational studies of fish intake or DHA levels and those using DHA 
supplementation is potentially attributable to artifacts caused by methodological differences, 
including different definitions of cognitive function or dementia, different analytical methods, 
and possibly even different definitions of ‘healthy’ controls.  
Intervention studies, even RCTs, have their own pitfalls. Contrary to RCTs with drugs, 
administration of nutritional supplements does not start from zero intake of the nutrient in the 
supplement. Indeed, individuals are already exposed to varying dietary sources of EPA and 
DHA, which may confound the true effect of the supplementation. Differing background DHA 
intakes, especially the very low DHA and EPA intakes in the USA, may also play a role in the 
lack of agreement. In principle, randomization should correct for different basal dietary EPA 
and/or DHA exposure in the intervention and control groups. Nevertheless, as the target 
population for an RCT, individuals may be selected who are more or less prone to suffer from 
insufficient dietary intake of the supplement to be used, e.g. hospitalized elderly who are at 
higher risk of undernutrition [124]. These individuals might benefit more from the 
supplementation than healthy community dwellers such as those included in a large primary 
prevention trial [120]. As already shown for RCT of fish oil supplementation in cardiovascular 
disease [26], overly optimistic estimates of effect sizes, poor patient adherence to a long 
course supplementation, and higher than anticipated losses to follow-up may all reduce the 
power of a trial and hence its ability to demonstrate significant differences.  
 Indeed, even the placebo can create bias; olive oil might have some protective effects 
against cognitive decline [128],while a placebo based on ω6 fatty acids such as linoleic acid 
might increase the risk of dementia [84]. The true difference between the intervention and 
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treatment groups would therefore be artificially minimized in the first case, but increased in 
the second. Of course, 240 mg olive oil is a very small quantity compared to the overall 
dietary intake of some populations but 1 g corn oil provides 0.6 g linoleic acid, which could 
contribute importantly to total intake of ω6 fatty acids. 
Another major limitation of most intervention studies is their poor selection of 
individuals who could actually benefit from a dietary supplement because of their low 
spontaneous DHA intake. In the clinical trials with DHA, different time courses and different 
durations of DHA supplementation or composition of the supplements make the results 
difficult to interpret. The duration of the supplementation is generally limited to a few weeks or 
months, which may be quite insufficient to reverse a chronic deficiency and the associated 
cognitive dysfunction despite the rapid plateau in plasma levels achieved in approximately 
one month after supplementation [101].  
 
6.2  Biological Issues 
If there really is a link between higher intake of DHA itself (or other ω3 fatty acids) and 
lower risk of AD, then further research is needed to identify and understand the biological 
processes that could mask this relationship and prevent the normal link between low DHA 
intake and low plasma DHA from being seen in AD. DHA synthesis and β-oxidation are both 
very low in humans [89] so, unlike in many animal models, in non-vegan humans, DHA intake 
has a very important effect on whole body DHA homeostasis [97]. To our knowledge, no 
study has yet examined the association of DHA and AD in vegans or other populations that 
strictly eat no fish. The brain is rich in DHA and brain DHA levels are relatively hard to 
manipulate after weaning, so it is somewhat more understandable that brain DHA levels could 
be the same in AD as in healthy, age-matched controls. Lipid peroxidation and other 
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degenerative processes linked to inflammation that play a key role in AD may degrade and 
deplete DHA but their quantitative impact on DHA levels would be small unless lipid 
peroxidation was occurring on a massive scale. If lipid peroxidation did consume brain DHA, 
one would expect DHA levels to decrease but not more so than the other long chain PUFA in 
the brain (mostly ARA and adrenic acid).  
Depression also is a factor that may contribute to AD, and two prospective studies 
have reported higher plasma ARA:DHA in more depressed subjects [107]. Interestingly, 
higher plasma phospholipid EPA and DHA was protective against decline in verbal fluency 
but only in the least depressed subjects; no such association was found with global cognitive 
decline or other tests in that study [104]. 
At DHA intakes up to 2 g/d, plasma phospholipid DHA concentrations increase in a 
dose-dependent, saturable manner in response to dietary DHA [101]. Red blood cell kinetic 
follows a similar pattern, but it takes a longer time to reach a steady state [101]. Peripheral 
DHA levels, in particular in plasma, may not adequately reflect DHA incorporation into neuron 
membranes. Red blood cells might be a better compartment to assess the link between 
habitual DHA intake and brain DHA. On the other hand, plasma DHA may be a more 
sensitive measure of short term dietary intake and release from membrane phospholipids 
after phospholipase cleavage. Plasma DHA might therefore better reflect the bioavailability of 
fatty acids as substrates for cycloxygenases and lipoxygenases but be poor predictors of the 
long-term effect of dietary DHA on brain aging.  
Rapoport [129] estimates that the healthy young adult human brain turns over DHA at 
a rate of about 4.5 mg/d. If Rapoport’s calculation is correct, why the necessary daily dose of 
DHA to impede cognitive decline in AD varies so widely (from as little as 180 mg/d to almost 
40 times that amount; Table 4) also needs to be understood. The turnover of DHA comprises 
its use for membrane replacement, β-oxidation, synaptic integrity, gene regulation and 
 29
DHA-AD PLR 2009-02-08 
synthesis of docosanoids and neuroprotectins but does not take into account factors such as 
DHA losses to lipid peroxidation which could contribute to a higher DHA requirement during 
aging or, especially, in AD [130]. Moreover, the amount of DHA that should be consumed to 
meet the brain’s requirement DHA is still not known.  
Whether brain DHA turnover changes with healthy aging, presence of an ApoE4 allele 
or during cognitive decline remains to be determined. Whole body β-oxidation of a single dose 
of 13C-DHA in healthy, young adults is very low (<5% in a one month follow-up; [131]), 
suggesting that, like the brain, the healthy, adult human body is not rapidly catabolizing large 
amounts of DHA relative to average DHA intakes common in North America (generally ≥100 
mg/d; [132, 133]). Therefore, a better understanding of DHA metabolism, including its 
transport and β-oxidation seems crucial to better assess the changes occurring during healthy 
aging and during cognitive decline. 
 
6.2.1.  DHA Metabolism During Healthy Aging 
There are no widely recognized criteria for healthy aging or healthy elderly controls. In 
research studies, mean ages of elderly groups can be as low as 50 y or as high as 75-80 y 
old. Identifying changes in ω3 PUFA metabolism that occur during healthy aging may help to 
determine how dietary DHA or EPA contributes to healthy aging and, by inference, how they 
might reduce the risk of cognitive decline and AD.  
We compared the plasma DHA response to a fish oil supplement in healthy elderly and 
young adults [134]. Our subjects were screened for clinical evidence of cardiovascular 
disease, chronic inflammation, thyroid, liver and renal disease, malnutrition, and even early 
indicators of diabetes. At baseline, both EPA and ARA were higher in elderly compared to 
young adults. During the fish oil supplementation phase, plasma DHA increased significantly 
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higher and more rapidly in the elderly, reaching a plateau after 2 weeks of supplementation 
whereas in young, plasma DHA was still increasing after 3 weeks [134]. EPA and ARA 
remained higher in elderly compared to young throughout the fish oil supplementation. Other 
reports confirm the likelihood that baseline fasting plasma EPA and DHA are somewhat 
higher in the healthy elderly [135-137]. These results suggest that long chain PUFA 
metabolism is subtly altered during healthy aging, due possibly to changes in their β-oxidation 
or perhaps to lower capacity of organs such as the brain to utilize EPA, DHA and ARA.  
We have also unpublished results using a unique tracer – uniformly carbon-13 (13C)-
labeled DHA - in young and elderly. Our preliminary results suggest that the incorporation of 
13C-DHA into plasma TG and free fatty acids is already different between young and healthy 
elderly subjects within the first four hours after its intake. In a follow-up of one month, overall 
β-oxidation of 13C-DHA was similar between young and elderly but four hours after the single 
oral dose of 13C-DHA, β-oxidation was significantly higher in the elderly, an effect 
corresponding possibly to the higher plasma incorporation of 13C-DHA 4 hours dosing. 
Therefore, our data suggest that ω3 PUFA metabolism changes mildly but significantly during 
healthy aging. Whether this would have any impact on risk of cognitive decline is still 
unknown.  
Not only do plasma ω3 PUFA levels and response to a supplement change during 
healthy aging, but the brain also seems to undergo important changes in lipid composition. 
Between 20 y old and 100 y old, the healthy brain loses 20% of its weight, 36% of its dry 
matter weight [119]. Lipid content is markedly affected by the brain atrophy associated with 
aging since cholesterol and phospholipids decrease by 47% and 42%, respectively [119]. 
Unfortunately, brain PUFA composition was not reported in this study. Nevertheless, it is clear 
 31
DHA-AD PLR 2009-02-08 
that better criteria to define healthy elderly controls are needed, which may avoid some of the 
conflicting data reported in relation to PUFA and cognitive deterioration in the elderly.  
 
6.2.2 Apolipoprotein E 
One of the biological factors that may mask the relationship between DHA and lower 
risk for AD is polymorphisms in ApoE. Around 23% of the Caucasian population carries, i.e. 
has at least one copy, of the ε4 allele of ApoE [138], which is the genetic risk factor most 
associated with late onset or sporadic AD. Premature cognitive decline in ApoE4 carriers 
occurs in midlife, a decade or more before the onset of MCI and/or AD [139]. Children aged 
11 years old with higher general intelligence had higher erythrocyte ω3 PUFA, but the 
correlation was only significant for those without the ε4 allele of ApoE [140]. The same 
population was retested at 64 years old and their general intelligence was even more highly 
positively correlated with erythrocyte ω3 PUFA, but there was still no correlation in carriers of 
ApoE4 [140].  
Two recent prospective studies indicate that ApoE4 carriers are not protected against 
dementia by higher fish intake [84, 86]. Nevertheless, one recent study evaluating the impact 
of fish oil on cognitive performance in the healthy elderly reported that after 26 weeks of 
supplementation with either 0.4 or 1.8 g/d of ω3 PUFA, ApoE4 carriers had improved scores 
on tests of the cognitive domain of attention compared to the placebo [120]. Plasma EPA and 
DHA concentrations were reported but no information was provided as to whether they 
changed differentially in relation to ApoE4 genotype. 
Response of plasma DHA and plasma lipids to a fish oil supplement is influenced by 
the ApoE4 genotype [141-143]. We have preliminary results on incorporation of EPA and 
DHA into plasma lipids of ApoE4 carriers and non-carriers that clearly support this gene-by-
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diet interaction [144]. We analyzed the plasma fatty acid profiles of 8 carriers and 20 non-
carriers of ApoE4, before and after 6 wk of 3 g/d of EPA and DHA combined [144]. In contrast 
to what we anticipated at baseline, ApoE4 carriers had significantly higher EPA and DHA in 
plasma TG. Unlike in non-carriers of ApoE4, EPA in plasma free fatty acids in ApoE4 carriers 
did not change nor did DHA change in plasma TG after the supplement. These recent data 
suggest that the ApoE4 interaction with PUFA metabolism is a nutrient-gene interaction which 
must be taken into account when assessing the risk for AD. 
In AD patients in the OmegAD study, weight gain and appetite improved in EPA+DHA 
group but only in those not carrying the ApoE4 allele [145]. Hence, DHA and/or EPA 
supplementation might also work through mechanisms that could contribute towards 
improved nutritional status of AD patients. Here again, the interaction with genetic 
polymorphisms deserves further research.  
 
6.2.3.  Other Nutrients in Fish 
If there really is no link between low DHA and risk of AD but there is a link to low fish 
intake, other nutrients in fish that are currently drawing less attention than ω3 PUFA may 
actually be the nutrients protective against AD. For instance, intake of fish protein may be 
protective against type 2 diabetes. In lean fish, protein is the most abundant nutrient [146]. 
Cod protein may affect glucose metabolism by improving insulin sensitivity [147] and may 
also lower plasma C-reactive protein [147] in insulin resistant men and women. Since much 
epidemiological evidence suggests that type 2 diabetes is associated with a 2-3 fold 
increased relative risk for AD [148, 149] and since aging itself is linked to somewhat 
increased prevalence of insulin resistance, improving insulin sensitivity by intake of fish 
protein may help in the management of whole body glucose metabolism [149]. Conversely, in 
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addition to ω3 PUFA, fish oil capsules may provide some protective lipid-soluble vitamins but 
contain no fish protein.  
The role of EPA (also found in fatty fish) in brain aging may have been underestimated. 
Indeed, higher plasma EPA but not DHA was strongly linked to lower risk of incident dementia 
in the Three City study [106]. The EPA:DHA ratio varies considerably across fish species. 
Whereas most fishes contain about twice as much DHA as EPA, the reverse is observed in 
Atlantic herring or shrimp [150]. Most studies used combinations of EPA and DHA which 
makes it difficult to discern specific roles and cognitive benefits of the individual ω3 PUFA 
[101].  
Other micro-nutrients found in fish may also exert protective effects on the brain, i.e. 
selenium, vitamins A and D, or vitamin B12 [94]. Plasma selenium concentration has been 
reported to correlate to that of plasma EPA and DHA [151]. In addition to long chain ω3 
PUFA, these nutrients might exert protective effects in the brain by various mechanisms, 
including the anti-oxidant properties of selenium, activation of vitamin D receptors and retinoic 
acid receptors in the brain by vitamins D [152] and A [153], respectively, and homocysteine-
lowering effects of vitamin B12 [154]. It is therefore very difficult to disentangle their respective 
effects. These nutrients might act as confounders in the relationship between fish intake and 
risk of AD, i.e. they would explain a protective effect wrongly attributed to DHA. Alternatively, 
they may also have synergistic effects which would enhance the protective action of DHA 
against brain aging. For instance, selenium is an anti-oxidant that may help protect DHA 
against lipid peroxidation. Similarly, DHA activates PPARs, which are a partner of 
dimerisation of RXR retinoid receptors activated by vitamin A derivatives [155].  
Supplements of ω3 PUFA could therefore be more efficacious if they included such 
synergistic nutrients. In that sense, the positive impact on several cognitive outcomes of a 
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supplement of DHA and lutein, a carotenoid, deserves further attention [123]. Indeed, some 
fish species such as salmon eat small invertebrates rich in carotenoid pigments which give 
them their color, and which are precursors of vitamin A. 
 
6.2.4  Fish as a Component of a Healthier Diet  
It may also be important to think in terms of dietary patterns rather than just the intake 
of specific nutrients or food types. For instance, in the Three City Study, when considered 
alone, fish intake was not significantly associated with decreased risk of dementia but this 
association was present when fish was jointly considered with daily consumption of fruits and 
vegetables [84]. Fish consumers are generally higher consumers of fruits and vegetables 
which provide antioxidants that help minimize the risk of lipid peroxidation [91] of long-chain 
PUFA. The DHA content of fish species may also vary considerably according to where they 
are caught or fish farming conditions [94]. 
Fish consumption is therefore widely viewed as a component of a healthy diet, one that 
also includes higher fruit and vegetable consumption that provide vitamin C, carotenoids, and 
polyphenols exerting potentially important anti-oxidant effects which could contribute to 
slowing down brain aging [91, 156-158]. Fish consumption is also a component of a 
Mediterranean dietary pattern whose protective effect against AD was recently described 
[100]. The combination of both long-chain ω3 PUFA and anti-oxidants which will protect them 
against peroxidation could therefore be necessary.  
 
6.2.5 Insufficient DHA or Excessive ω6 PUFA? 
 DHA status should not be considered independently of ω6 PUFA intake. Indeed, DHA 
and EPA compete with ARA for the sn-2 position on membrane phospholipids [101]. Is AD 
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associated with low DHA intake or is it rather a question of too much ω6 PUFA intake? In the 
Three City study, higher plasma ARA:DHA was associated with increased risk of incident 
dementia whereas plasma concentrations of ARA or DHA alone were not [106]. Normal 
individuals could therefore potentially have a cognitive benefit from high intake of DHA and/or 
EPA but only if they correct an excessive intake of ω6 fatty acids [159]. A dietary trial in which 
healthy adult men consumed a ratio of linoleic acid to alpha-linolenic acid of 4:1 or 10:1 
showed that lowering linoleic acid intake was associated with higher plasma phosholipid EPA 
and lower plasma ARA:EPA, but did not modify ARA or DHA [160]. 
 
7. ANIMAL STUDIES  
The transgenic mouse - Tg2576 - with the APPswe mutation is the main animal model 
used to study the dietary effects of ω3 PUFA on AD. These mice exhibit memory loss and Aβ 
deposition. In two studies, adult Tg2576 mice were given different levels of dietary ω3 PUFA 
(control diet, ω3 deficient diet, and the same ω3 deficient diet supplemented with DHA) for 
about 100 days [161, 162]. ω3 PUFA deficiency leads to a loss of key pre- and postsynaptic 
markers essential for cognition. Indeed, ω3 PUFA deficiency decreased N-methyl-D-aspartate 
receptor subunits (pre-synaptic) in the cortex and hippocampus of mice and also decreased 
Ca2+/calmodulin-dependent protein kinase (postsynaptic) in the cortex. These effects were 
significantly higher in Tg2576 mice compared to the non-transgenic controls [161].  
Reduction of dietary ω3 PUFA resulted in a 80-90% decrease of the p85 α subunit of 
phosphatidylinositol 3-kinase and the post-synaptic actin-regulating protein, drebrin, a change 
also observed in the brains of AD patients. ω3 PUFA deficiency also increased caspase-
cleaved actin content and oxidative stress markers in the brain cortex [162]. Conversely, mice 
fed a ω3 deficient diet supplemented with DHA were partly protected against these effects 
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and behavioral deficits. DHA-supplemented mice also exhibited improved spatial memory 
[161, 162]. A 40% decrease of the number and burden of amyloid plaques was observed in 
the same transgenic mouse model submitted to a high DHA diet (containing 0.6% DHA) 
compared to a low DHA diet (ω6:ω3 of 85:1, with 6% fat as safflower oil), but not control diet 
(ω3:ω6 of 7:1). DHA treatment also lowered the levels of Aβ42 but not Aβ40 in the cortex of 
these animals [163]. 
Conversely, in a double transgenic mouse model of AD expressing mutant genes for 
amyloid precursor protein and presenilin 1, a diet containing 4% fish oil with DHA as 5.7% of 
total fatty acids did not modify the hippocampal levels of either soluble or insoluble Aβ 
compared to mice receiving a standard control diet [159]. In that study, the high ω3 PUFA diet 
did not improve or protect the cognitive performance of the transgenic compared to non-
transgenic mice. Brain levels of ω6 PUFA were strongly positively correlated with cognitive 
impairment, whereas no correlations existed between brain ω3 PUFA levels and cognitive 
performance in transgenic or non transgenic mice [159]. However, the small number of 
animals in this experiment (n = 8 in each group) may have hampered detection of a significant 
difference despite the decreases of 25% and 17%, respectively, in soluble Aβ40 and Aβ42 in 
the group receiving the DHA-enriched diet.  
More recently, in the Tg-AD triple transgenic mouse model of AD that exhibits both Aβ 
and tau pathologies, soluble Aβ40 and Aβ42 levels were significantly reduced after 6 months 
of dietary supplementation with DHA. After 9 months of supplementation, the DHA diet 
significantly reduced levels of soluble Aβ40 but not Aβ42. Insoluble Aβ levels were unchanged 
by the diet. DHA also reduced the accumulation of tau and phosphorylated tau in the soluble 
fractions of protein extracted from the whole brain [164]. 
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Other studies using non-transgenic animal models seem to confirm the protective 
effect of DHA on AD. Indeed, in a model of cognitive impairment in which the rats received an 
intracerebral infusion of Aβ40, dietary DHA provided a beneficial effect against the impairment 
of learning ability [56, 165, 166]. In these studies, DHA also decreased Aβ40 accumulation 
after its infusion. Some but not all animal studies suggest that dietary ω3 PUFA depletion 
could potentiate markers of AD in the rodent brain, i.e. such as Aβ accumulation, amyloid 
plaques and cognitive impairment, whereas DHA seems to have a beneficial effect on some 
of these markers. Nevertheless, some inconsistencies exist between studies, including 
differences in the effect of DHA on the levels of Aβ and the impact of ω3 PUFA 
supplementation on cognitive performances. Furthermore, few effects of DHA 
supplementation on tests of cognitive performance or behaviour have been reported in these 
AD models.  
A good animal model of AD is of primary importance as it permits investigation of 
mechanisms of the pathology which cannot be explored in humans, even if these animals 
incompletely express clinical symptoms or markers of AD neuropathology. One lesser known 
animal model of AD is the primate, Microcebus Murinus (mouse lemur), which naturally 
exhibit age-related brain changes closer to those in humans than presently seen in rodent 
models. Neurodegeneration in the aged mouse lemur is characterized by brain atrophy, 
presence of amyloid plaques, cytoskeletal tau pathology and a loss of cholinergic neurons. 
Aged mouse lemurs lose their cognitive and social capacities and exhibit certain age-
associated similarities with human AD, while animals with elderly normal brain aging maintain 
memory function and social interaction [167]. 
A major limitation of human studies is their inability to have access to the brain. 
Moreover, post-mortem studies are based on small and highly selected clinical series. Animal 
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studies are therefore complementary approaches to verify the hypotheses on the 
mechanisms of action of fatty acids in animal brains.  
 
8.  BRAIN GLUCOSE UPTAKE: AN EMERGING MECHANISM  
Assuming that the difficulty linking plasma or brain DHA to cognitive decline in the 
elderly is mostly methodological, i.e. that higher fish intake really does reduce the risk of AD 
or other forms of cognitive decline in the elderly, the mechanism of such an important effect 
still needs to be defined. An overview of the biological roles of DHA that have been well 
established during the past 30 years is given in the section - Biological Functions of DHA; 
each of these roles could in some way be implicated in protecting the brain against AD. We 
add here a mechanism that is emerging as potential link between low DHA and risk of 
cognitive decline in the elderly – that of control of brain glucose uptake.   
During healthy aging, brain glucose uptake decreases significantly in specific cortical 
regions [168], an effect that is more pronounced in the elderly with deteriorating cognitive 
function such as AD [169]. Experimental data support the hypothesis that ω3 PUFA intake 
could affect neuronal activity by altering brain fuel supply and hence energy metabolism. The 
main energy requirement of the brain is for Na+/K+ pump activity in nerve terminals and for 
oxidative phosphorylation, both of which are decreased in ω3 PUFA deficient rats [170, 171]. 
Glucose utilization, glucose transporter 1 (GLUT1) immunostaining and the amount of the 
endothelial glucose transporter GLUT1 protein are all decreased in the cerebral cortex in a rat 
model of dietary ω3 PUFA deficiency characterized by lower brain DHA content [171, 172]. 
GLUT1 is located in endothelial cells of brain microvessels and at the endfoot processes of 
astrocytes and is therefore the gateway for glucose entry into the brain. In a more recent and 
preliminary study, rats fed a DHA-supplemented diet had increased GLUT1 expression [173]. 
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These data suggest a possible role of DHA in the control of GLUT1 expression and glucose 
transport into the brain. 
This emerging role of ω3 PUFA and/or DHA in brain energy metabolism could be 
linked to brain glucose hypometabolism, which seems to be the earliest identified change in 
AD, occurring 25-20 years before the clinical horizon [174]. It is therefore now possible to 
address the questions: could DHA promote brain glucose metabolism in the elderly, and could 
ω3 PUFA intake be a useful dietary approach to correcting impaired cerebral glucose 
metabolism during aging thereby reducing the risk of aging-related cognitive decline and AD?  
 
9. DISCUSSION 
AD has a major impact on the healthcare system and has no widely accepted 
treatment. Developing effective strategies to reduce its risk and possibly improve its treatment 
is therefore a matter of high importance. The effectiveness of strategies involving DHA to 
reduce the risk of AD depends on a good understanding of how low intake or tissue levels of 
DHA would increase the risk of AD or other forms of cognitive decline in the elderly. Since the 
extensive report of Maclean et al in 2005 [175], numerous important contributions have been 
made in this field. A fairly solid basis now exists for believing that low fish and DHA intake 
contribute significantly to the risk of AD. Lower blood DHA is also fairly convincingly linked to 
a higher risk of cognitive decline and AD. However, the overall literature on static 
measurements of either blood or brain DHA shows no statistical difference in AD compared to 
healthy controls. Thus blood DHA needs to be assessed in relation to cognitive status and, by 
itself, is not presently a very useful marker actual or impending cognitive decline. Clinical trials 
published to date that involve DHA supplementation have also not been that promising. 
Hence, we agree with the conclusion of Maclean et al [175] that more research is definitely 
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needed. However, we would suggest that the focus could be less on whether low dietary DHA 
is a factor increasing the risk of cognitive decline or AD and could be more on establishing 
how DHA would be biologically linked to AD. 
Such mechanistic research is essential if DHA or other PUFA are to find a useful role 
as nutritional supplements protecting against risk of AD or other forms of dementia, well 
designed RCTs are urgently needed that target individuals with low dietary DHA intake and 
raised risk of cognitive decline but who are not yet demented. It is not yet clear whether 
dietary DHA only has a preventive role, i.e. in risk reduction, or whether it could also be used 
to treat AD; if the latter, how early DHA supplements should be started is uncertain. There is 
also a need to establish which categories of cognitive decline are likely to be responsive to 
higher intake of fish or DHA or other PUFA; i.e. AD, vascular dementia, mixed or other forms. 
Consensus is also needed on definitions of AD and criteria to be used for subject selection so 
that independent studies can be compared more directly. The optimal duration of 
supplementation still needs to be defined, i.e. not too short so as to be inconclusive, as do 
doses and an optimal EPA:DHA ratio that are effective but do not increase risk of brain 
damage due to lipid peroxidation.  
In the absence of easily accessible and specific biomarkers of AD, exploratory trials 
are needed to assess the impact of various doses and proportions of EPA and DHA on 
intermediate biomarkers i.e. oxidative stress, inflammation, and Aβ concentration in older 
persons. Animal models may be able to help identify both mechanistic aspects of PUFA 
involvement in neurodegeneration and suitable biological markers of incipient cognitive 
decline.  
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Table 1 
Prospective observational studies relating fish or dietary DHA consumption to risk of dementia or cognitive decline. 
Study 
 
N Age 
(years) 
Food or nutrient Outcome Results (multivariate models) 
Rotterdam Study 
(The Netherlands) 
[81] 
5386 ≥ 55 Fish 
Total fat 
SFA 
All cause dementia 
AD 
VaD 
Mean follow-up 2.1 years 
Protective association of fish consumption (at least 18.5 
g/d) with all-cause dementia and AD 
Increased risk of vascular dementia with total fat and 
saturated fat 
Rotterdam Study 
(The Netherlands) 
[82] 
5395 ≥ 55 Total, SFA, trans fat, 
MUFA, total PUFA, total ω6 
PUFA, total ω3 PUFA 
All cause dementia 
AD 
VaD 
Mean follow-up 6.0 years 
No association with any class of fatty acids 
PAQUID 
(France) 
[83] 
1416 ≥ 68 Fish 
 
All cause dementia 
AD 
7 years of follow-up 
Protective association of at least weekly fish consumption 
against all-cause dementia and AD 
Chicago Health and Aging 
Project 
 (USA) 
 [87] 
815 65 - 94 Fish 
Total ω3 PUFA 
EPA, DHA 
AD 
Mean follow-up 3.9 years 
Protective association with fish consumption, total ω3 
PUFA and DHA 
No association with EPA 
Chicago Health and Aging 
Project 
 (USA) 
[88] 
3718 ≥ 65 Fish 
Total ω3 PUFA 
EPA, DHA 
Cognitive decline over 6 years (global 
measure from 4 standardized tests) 
At least weekly fish consumption associated with slower 
cognitive decline 
No association with ω3 PUFA, EPA or DHA 
Cardiovascular Health 
Cognition Study 
[86] 
2233 ≥ 65 Fish All cause dementia 
AD 
VaD 
Protective association with nonfried fish for AD only in 
ApoE4 negative (N=1570); NS when additionally adjusted 
for education and income 
No association in ApoE4 positive (N=474) 
 69
DHA-AD PLR 2009-02-08 
 70
Three City Study (France) 
[84] 
8085 ≥ 65 Fish All cause dementia 
AD 
Fish associated with lower risk of all-cause dementia only 
in ApoE4 negative (N=5944) 
No association in ApoE4 positive (N=1479) 
No significant association with AD 
Zutphen Elderly Study 
[176] 
 
342 69-89 Fish Cognitive decline over 3 years in MMSE 
score 
Fish inversely but not significantly associated with cognitive 
decline 
Zutphen Elderly Study 
[127] 
210 70 - 89 Fish 
EPA+DHA 
Cognitive decline over 5 years Fish and EPA+DHA intake associated with less cognitive 
decline 
Cardiovascular Risk Factors, 
Aging and Dementia Study 
(Finland) 
[85] 
1449 60 - 80 Fish 
SFA 
PUFA 
Cognitive performance 21 years later 
MCI 
SFA associated with poorer cognitive function and 
increased risk of MCI 
Higher intake of PUFA and fish associated with better 
performances 
Framingham Heart Study 
[89] 
488 76 Fish 
DHA 
All-cause dementia 
AD 
Mean follow-up 9.1 years 
No significant association 
Atherosclerosis Risk in 
Communities Study 
[177] 
7814 50-65 Total ω3 and ω6 PUFA 
Long-chain ω3 and ω6 PUFA 
Cognitive decline over 9 years Higher long-chain ω3 PUFA and balanced ω6/ω3 ratio 
associated with lower risk of cognitive decline, especially 
for verbal fluency and among hypertensives 
 
PAQUID: Personnes Agées QUID 
SFA: Saturated fat 
MUFA: Mono-unsaturated fat 
PUFA: Polyunsaturated fat 
AD: Alzheimer disease 
MCI: Mild Cognitive Impairment 
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Table 2 
 
Blood docosahexaenoic acid (% of total fatty acids) in relation to cognitive status in the 
elderly.  
Reference Type of study, 
duration follow-up 
Cognitive status  N Age (y) 
Mean 
DHA 
            
A. PLASMA PL            
Tilvis et al., [178] Cross-sectional AD 11 69 7.4 ± 0.6 
  VD 19 73 6.4 ± 0.4 
      
Corrigan et al. [108] Cross-sectional Control 49 74 5.6 ± 0.6 
  MID 6 81 5.5 ± 0.2 
  AD 36 81 4.4 ± 0.9 
      
Conquer et al. [179] Cross-sectional Control 19 77 4.6 ± 0.4 
  CIND 27 83 3.7 ± 0.2 
  AD 13 83 3.1 ± 0.2 
      
Laurin et al.[105] Cross-sectional Control - all 79 77 2.1 ± 0.8 
  ApoE4 non-carriers 65 N/A 2.1 ± 0.6 
  ApoE4 carriers 13 N/A N/A 
      
  CIND 43 79 2.1 ± 0.8 
  Demented - all 52 81 2.3 ± 0.8 
  ApoE4 non-carriers 28 N/A 2.4 ± 0.7 
  ApoE4 carriers 24 N/A N/A 
      
Laurin et al. [105] Prospective, 5 y Control 52 - 2.0 ± 0.7 
  CIND 16 - 2.1 ± 0.8 
  Demented 11 - 2.7 ± 1.2 
      
Manzato et al., [180] Cross-sectional Control 98 72 3.3 ± 1.1 
  CIND 93 82 3.1 ± 1.1 
      
Beydoun et al. [103] Prospective, 6 y Control 2111 56 2.9 ± 0.9 
  CD 140 57 3.0 ± 0.9 
      
B. PLASMA PC      
Conquer et al. [179]  Cross-sectional Control 19 77 4.9 ± 0.4 
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  CIND 27 83 3.6 ± 0.2 
  AD 13 83 3.2 ± 0.2 
      
Schaefer et al. [89] Prospective, 9 y CD 899 76 >4.2% = lower 
risk for CD 
      
      
C. PLASMA CE       
      
Tilvis et al., [178] Cross-sectional AD 11 69 1.3 ± 0.1 
  VD 19 73 1.1 ± 0.1 
      
Corrigan et al. [108] Cross-sectional Control 49 74 0.4 ± 0.4 
  MID 6 81 2.0 ± 1.0 
  AD 36 81 0.6 ± 0.5 
      
Tully et al. [181] Cross-sectional Control 45 69 1.2 ± 0.9 
  CD
1 42 76 0.6 ± 0.5 
  AD2 42 75 0.7 ± 0.7 
      
Beydoun et al. [103] Prospective, 6 y Control 2111 56 0.5 ± 0.2 
  CD 140 57 0.5 ± 0.2 
      
Dullemeijer et al. 
[107] 
Prospective, 3 y  404 60 every doubling 
in ω3 PUFA 
proportion ↓ 
rate (9-12%) in 
speed-related 
cognitive 
domains  
Dullemeijer et al. 
[107] 
Cross-sectional  807 60 No association 
with any of the 
5 cognitive 
domains 
D. PLASMA TOTAL FA     
Cherubini et al., [182] Cross-sectional Control 725 74 2.3 (2.2 - 2.3) 
  CIND 153 81 2.2 (2.1 - 2.3) 
  Dementia 57 85 2.0 (1.8 - 2.2) 
      
Samieri et al. [106] Prospective, 4 y Control 1149 74 2.4 ± 0.8 
      
  Dementia 65 78 2.2 ± 0.8 
E. ERYTHROCYTES      
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Tilvis et al., [178] Cross-sectional AD 11 69 10.6 ± 1.3 
  VD 19 73 5.6 ± 0.8 
      
Corrigan et al., [108] Cross-sectional Control 49 74 3.2 ± 2.5 
  MID 6 81 5.6 ± 1.8 
  AD 36 81 4.4 ± 2.2 
      
Heude et al. [104] Prospective, 4 y Control 219 69 6.3 ± 1.1 
  CD 27 69 5.9 ± 1.0 
      
Boston et al. [125] Cross-sectional Control 10  -  41.2 ± 20.93 
  AD 22 81 35.3 ± 21.53 
      
Wang et al. [183] Cross-sectional CD 13 77 5.4 ± 1.6 
  AD 10 75 4.2 ± 1.2 
      
AD: Alzheimer's disease; ApoE4: Apolipoprotein E ε4; CE: cholesteryl esters; CIND: cognitive 
impaired non demented; CD: cognitive decline; MID: multi-infarct dementia; PC: 
phosphatidylcholine; PUFA: polyunsaturated fatty acids; TPL: total phospholipids; VD: Vascular 
dementia 
1 1st quartile of AD      
2 4th quartile of AD      
3 μg/g      
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Table 3 
 
Docosahexaenoic acid in brain lipids in the healthy elderly compared to Alzheimer’s disease 
(AD).  
Docosahexaenoic Acida Reference Cognitive 
status 
N Age 
(y) PE PC Total PL Free
FRONTAL CORTEX           
Brooksbank et al., [184] Control 6 73 25,9 2,5   
 AD 6 75 25,9 2,5   
Soderberg et al. [110]1 Control 8-10 n/a 23.5 1.4   
 AD 8-10 n/a 12.6 0.8   
Soderberg et al. [110]2 Control 8-10 n/a 4.6 TR   
 AD 8-10 n/a 2.0 TR   
Guan et al. [113] Control 13 72 2129b 491b   
 AD 15 80 2512 361   
Skinner et al. [115]1 Control 10 68   18.6  
 AD 9 79   17.3  
Skinner et al. [115]2 Control 8 68   3.6  
 AD 7 79   4.6  
                
PARAHIPPOCAMPUS         
        
Corrigan et al. [111] Control 6 73 20.7 1.6   
 AD 8 77 20.5 1.4   
Skinner et al. [115]1  Control 10 68   16.9  
 AD 12 79   16.6  
Skinner et al. [115]2  Control 8 68   5.1  
 AD 7 79   5.0  
                
HIPPOCAMPUS        
Soderberg et al. [110] Control 8-10 n/a 16.9 0.9   
 AD 8-10 n/a 7.9 0.6   
Prasad et al. [114] Control 9 78 1017b 121b   
 AD 9 78 557 84   
Lukiw et al., [19] Control 6 69    55c 
 AD 6 70    25c 
                
AD: Alzheimer's disease; n/a: not available; PC: phosphatidylcholine; PE: 
phosphatidylethanolamine; PL: phospholipids; TR: Trace 
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a Unless otherwise noted, docosahexaenoic acid values are % of total fatty acids 
b nmol/g wet tissue    
c estimated  from Figure 5 of Lukiw et al., [19], nmol/mg protein 
1 Gray matter    
2 White matter     
 
 
 75
DHA-AD PLR 2009-02-08 
Table 4 
 
Impact of ω3 PUFA supplementation in the elderly with dementia or declining cognitive 
function. 
 
Age Supplement Dose (g) Duration 
(mo) 
Reference Cognitive 
status 
N 
(y)        
Measures 
DTCD 10 83 None   12 6% lower scores Terano et al. 
[124] DTCD 10 83 DHA 4.3 12 17% higher scores 
        
Control 8 78 DHA + EPA 0.6 + 0.5 6 75% of subjects 
improveda 
Suzuki et al. 
[185] 
CD  22 78 DHA + EPA 0.6 + 0.5 6 55% of subjects 
improveda 
        
MCI 9 70 P (olive oil) 0.24 3 No change Kotani et al. 
[186] MCI 12 67 DHA + ARA 
d 
0.24 3 8 - 15% higher 
scoresb 
 AD 8 67 DHA + ARA 
d 
0.24 3 No change 
        
AD 85 73 P (corn oil)/ 
DHA + EPA 
4.0/ 
1.7 + 0.6  
6/6 No changec Freund-Levi et 
al. [121] 
AD 89 73 DHA + EPA 1.7 + 0.6  12 No changec 
Chiu et al., 
[122] CIND 14 70-81
DHA + EPA 0.7 + 1.1 6 
No change 
 CIND 9 70-81 P (olive oil) 1.8 6 significant 
improvement in 
ADAS-cog test 
compared to P 
 AD 10 70-81 DHA + EPA 0.7 + 1.1 6 No change 
 AD 13 70-81 P (olive oil) 1.8 6 No change 
         
Boston et al 
[125] 
AD 19 81 Ethyl-EPA 1 3 No change 
        
AD: Alzheimer's disease; ARA: arachidonic acid; CD: cognitive decline; DHA: docosahexaenoic 
acid; DTCD dementia from thrombotic cerebrovascular disease EPA: eicosapentaenoic acid; MCI: 
mildly cognitive impaired; MMD: mild to moderate dementia; NS: not significant; P: placebo. 
a % of subjects with improved cognitive score       
b attention and memory tests    
c Except in subjects with scores >27 on the Mini-mental state exam 
d  In unknown proportions    
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FIGURE LEGENDS  
 
Figure 1 
Blood docosahexaenoic acid (DHA; % control) as calculated from the values reported 
in the published prospective studies listed in Table 2. As a % of each study’s own controls, 
overall mean plasma DHA value for the two data sets showing all causes of dementia 
including AD was 114±22 (mean±SD; black bars). For the four data sets reporting other forms 
of cognitive decline excluding dementia or AD, it was 100±5 (gray bars). As reported in the 
original studies, only the data of Heude et al [104] reported DHA significantly different from 
each study’s own control values (100%; * p<0.05). Note that two other published prospective 
studies were excluded from this analysis since they had no control group per se [89, 107]. 
CE: plasma cholesteryl esters, PL: plasma phospholipids, RBC: red blood cell total lipids, 
TFA: plasma total fatty acids.  
 
Figure 2 
Blood docosahexaenoic acid (DHA; % control) in all causes of dementia or dementia 
excluding Alzheimer’s disease (AD) as calculated from the values reported in the published 
prospective studies listed in Table 2. DHA values different from each study’s own control 
values (100%) as reported in the original study are identified by an asterisk (* p<0.05). As a % 
of control, overall mean blood DHA value for the nine data sets reporting all cause dementia 
including AD was 93±31 (mean±SD; black bars). For the nine data sets reporting other forms 
of cognitive decline except AD, it was 141±131 (gray bars). If the data of Corrigan et al (1991) 
[108] are considered to be an «outlyer», the overall means for all causes of dementia 
including AD become 79±20 and 82±20 for other forms of cognitive decline. Hence, even 
within studies, these cross-sectional studies on various forms of cognitive decline show wide 
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variability in blood DHA relative to controls. Note that two other published cross-sectional 
studies were excluded from this analysis since they had no control group per se [183, 187]. 
CE: plasma cholesteryl esters, PC: plasma phosphatidylcholine, PL: plasma phospholipids, 
RBC: Red blood cell total lipids, TFA: plasma total fatty acids.  
 
Figure 3. 
Docosahexaenoic acid (DHA) in phosphatidylethanolamine (PE), phosphatidylcholine 
(PC), total phopholipids (TPL), or as free DHA from Alzheimer’s disease brain samples. In two 
studies, gray matter (A) was distinguished from white matter (B). Data are shown as % control 
as calculated from the original data reported in Table 3 (*p<0.05, as reported in the original 
study). Compared to controls (100%), lower DHA was most consistently seen in hippocampus 
(3 studies), was not significantly different from control in parahippocampus (2 studies) or 
frontal cortex (4 studies), which had the most variability. 
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